Intravenous methotrexate at a dose of 1 g/m 2 incorporated into RCHOP prevented CNS relapse in high‐risk DLBCL patients: A prospective, historic controlled study-Reference-Cited by-同舟云学术

Intravenous methotrexate at a dose of 1 g/m 2 incorporated into RCHOP prevented CNS relapse in high‐risk DLBCL patients: A prospective, historic controlled study

Published:2020-01-22 Issue:4 Volume:95 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Wang Wei¹^ORCID,Zhang Yan¹,Zhang Lu¹,Yang Chen¹,Feng Jun¹,Cai Huacong¹,Chen Miao¹,Cao Xinxin¹,Zhuang Junling¹,Zhu Tienan¹,Duan Minghui¹,Zhang Wei¹,Li Jian¹,Zhou Daobin¹

Affiliation:

1. Department of Hematology Peking Union Medical College Hospital Beijing China

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25723

Reference10 articles.

1. Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

2. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

3. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma